Peter M. Tessier
`Albert M. Mattocks Professor
`Departments of Pharmaceutical Sciences, Chemical Engineering and Biomedical Engineering
`Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109
`734.763.1486, ptessier@umich.edu
`
`EDUCATION
`2003
`
`
`
`1998
`
`
`
`University of Maine
`
` University of Delaware
`
`
`Ph.D., Chemical Engineering
`Dissertation: “Fundamentals and applications of nanoparticle interactions and self-
`assembly”
`Advisors: Abraham M. Lenhoff and Stanley I. Sandler
`B.S., Chemical Engineering
`
`
`
`Co-Valedictorian
`
`
`PROFESSIONAL EXPERIENCE
`Albert M. Mattocks (Endowed) Professor
`2017-present
`University of Michigan, Departments of Pharmaceutical Sciences, Chemical
`Engineering and Biomedical Engineering, Biointerfaces Institute
`Richard Baruch M.D. Career Development (Endowed) Professor
`Rensselaer Polytechnic Institute, Department of Chemical & Biological Engineering,
`Center for Biotechnology & Interdisciplinary Studies
`Richard Baruch M.D. Career Development (Endowed) Associate Professor
`Rensselaer Polytechnic Institute, Department of Chemical & Biological Engineering,
`Center for Biotechnology & Interdisciplinary Studies
`Alexander von Humboldt Fellow
`Max Planck Institute for Biochemistry (Martinsried, Germany)
`Host: F. Ulrich Hartl
`Associate Professor
`Rensselaer Polytechnic Institute, Department of Chemical & Biological Engineering,
`Center for Biotechnology & Interdisciplinary Studies
`*granted early tenure (December 2012, promotion effective July 2013)
`Assistant Professor
`Rensselaer Polytechnic Institute, Department of Chemical & Biological Engineering,
`Center for Biotechnology & Interdisciplinary Studies
`American Cancer Society Postdoctoral Fellow
`Whitehead Institute for Biomedical Research (MIT)
`Advisor: Susan Lindquist
`
`2016-2017
`
`2014-2016
`
`2014-2015
`
`
`2013-2016
`
`2007-2013
`
`2003-2007
`
`ACADEMIC HONORS
`2018
`2016
`2015
`
`2015
`
`2014
`
`
`
`Fellow, American Institute for Medical and Biological Engineering
`Young Investigator Award, Biochemical Engineering Journal (Dublin, Ireland)
`Invited participant, USA National Academy of Engineering Frontiers of Engineering
`Symposium
`Young Investigator Award, Division of Biochemical Technology, American
`Chemical Society
`Young Scientist Award, World Economic Forum (Tianjin, China)
`
`1 of 8
`
`Fresenius Kabi
`Exhibit 1002A
`
`

`

`2014-2015 Alexander von Humboldt Fellowship for Experienced Researchers
`2010-2015 National Science Foundation CAREER Award
`2010-2014
`Pew Scholar Award in Biomedical Sciences
`2014
`
`Rensselaer Dept. of Chemical & Biological Engineering Teaching Award
`2013
`
`Rensselaer School of Engineering Teaching Excellence Award
`2012
`
`Rensselaer Early Career Award
`2012
`
`Rensselaer School of Engineering Research Excellence Award
`2012
`
`Allan P. Colburn Lectureship, Univ. of Delaware
`2004-2007 American Cancer Society Postdoctoral Fellowship
`2004
`
`National Institutes of Health Postdoctoral Fellowship (declined)
`2002
`
`W.H. Peterson Award, Best Student Presentation (BIOT), ACS National Meeting
`2002
`
`First Place, Colorado Protein Stability Conference Poster Session
`2001
`
`Teaching Fellow, Dept. of Chemical Eng., Univ. of Delaware
`2001
`
`Pigford Teaching Assistant Award, Dept. of Chemical Eng., Univ. of Delaware
`2000
`
`Semi-Finalist, Discover Magazine Award for Technological Innovation
`1999-2002 NASA Graduate Fellowship
`1998
`
`Co-Valedictorian, Univ. of Maine
`
`PATENTS
`Lindquist S.L., Krishnan R., Tessier P.M., “Devices from prion-like proteins”, US Patent 11/916,983
`(2009).
`
`
`
`BOOK CHAPTERS
`Tessier P.M., Lindquist S.L., “Unraveling molecular mechanisms and structures of self-perpetuating
`prions”, in Protein Misfolding Diseases: Current and Emerging Principles and Therapies, John Wiley
`& Sons. Dobson, C.M., Kelly, J.W. and Ramirez-Alvarado, M. Eds., (2010).
`
`
`JOURNAL PUBLICATIONS [57 published papers or papers in press, *=corresponding author, †=undergraduate
`student, [ ] = number of citations as of 1/2019, 3772 citations total (Google Scholar), average of 66 citations per paper, h-
`index=31 (Google Scholar)]
`1. Zhang, Y., Rabia, L.A., Starr, C.G., Ludwig, S.D., Gupta, P., Walker, L.M., Julian, M.C., Tessier,
`P.M.,* “Physicochemical rules for identifying monoclonal antibodies with drug-like specificity”, in
`review (2019).
`2. Stimple, S.D., Kalyoncu, S., Desai, A.D., Mogensen, J.E., Spang, L.T., Asgreen, D.J., Staby, A.,
`Tessier, P.M.,* “Sensitive detection of glucagon aggregation using amyloid fibril-specific
`antibodies”, in review (2019).
`3. Alam, M.E., Barnett, G.V., Slaney, T.R., Starr, C.G., Das, T.K., Tessier, P.M.,* “Deamidation
`compromises antibody colloidal stability and enhances aggregation in a pH-dependent manner”, in
`review (2019).
`4. Julian, M.C., Rabia, L.A., Desai, A.A., Arsiwala, A., Kane, R.S., Tessier, P.M.,* “Nature-inspired
`design and evolution of anti-amyloid antibodies”, in review (2018).
`5. Starr, C.G., Tessier, P.M.,* “Selecting and engineering monoclonal antibodies with drug-like
`specificity”, Current Opin Biotech, in press (2019).
`6. Rabia, L.A. Zhang, Y., Ludwig, S.D., Julian, M.C., Tessier, P.M.,* “Net charge of the
`complementarity-determining regions is a key predictor of antibody specificity”, Protein Eng Des
`Sel, in press (2019).
`7. Rabia, L.A., Desai, A.A., Jhajj, H.S., Tessier, P.M.,* “Understanding and overcoming trade-offs
`between antibody affinity, specificity, stability and solubility”, Biochem. Eng. J., 137, 365 (2018).
`[1]
`
`2 of 8
`
`Fresenius Kabi
`Exhibit 1002A
`
`

`

`8. Alam, M.E., Geng, S.B., Bender, C., Ludwig,† S.D., Linden, L., Hoet, R., Tessier, P.M.,*
`“Biophysical and sequence-based methods for identifying monovalent and bivalent antibodies with
`high colloidal stability”, Mol Pharm, 15, 150 (2018).
`9. Tiller, K.E., Li, L., Kumar, S., Julian, M.C., Garde, S., Tessier, P.M.,* “Arginine mutations in
`antibody complementarity-determining regions display context-dependent affinity/specificity trade-
`offs”, J Biol Chem, 292, 16638 (2017). [8]
`10. Tiller, K.E., Chowdhury, R., Li, T., Ludwig, S.,† Sen, S.,† Maranas, C., Tessier, P.M.,* “Facile
`affinity maturation of antibody variable domains using natural diversity mutagenesis”, Front
`Immunol, 8, 986 (2017). [2]
`11. Julian, M.C., Li, L., Garde, S., Wilen, R.,† Tessier, P.M.,* “Efficient affinity maturation of antibody
`variable domains requires co-selection of compensatory mutations to maintain thermodynamic
`stability”, Sci Rep, 7, 45259 (2017). [17]
`12. Zhao, J., Huvent, I., Lippens, G., Eliezer, D., Zhang, A., Li, Q., Tessier, P.M., Linhardt, R.J.,
`Zhang, F., Wang, C.,* “Glycan determinants of heparin-tau interaction," Biophys J, 112, 921
`(2017). [14]
`13. Nilvebrant, J.,* Tessier, P.M., Sidhu, S.S., “Engineered autonomous human variable domains”,
`Curr Pharm Des, 22, 1 (2016). [9]
`14. Geng, S.B., Wu, J., Alam, M.E., Schultz, J.S., Dickinson, C.D., Seminar, C.R.,† Tessier, P.M.,*
`“Facile preparation of stable antibody-gold conjugates and application to affinity-capture self-
`interaction nanoparticle spectroscopy”, Bioconjug Chem, 27, 2287 (2016). [5]
`15. Geng, S.B., Wittekind, M., Vigil, A. Tessier, P.M.,* “Measurements of monoclonal antibody self-
`association are correlated with complex biophysical properties”, Mol Pharm, 13, 1636 (2016). [9]
`16. Osborne, D.M., Fitzgerald, D.P., O'Leary, K.E., Anderson, B.M., Lee, C.C., Tessier, P.M., McNay,
`E.C.,* “Intrahippocampal administration of a domain antibody that binds aggregated amyloid-β
`reverses cognitive deficits produced by diet-induced obesity”, Biochim Biophys Acta, 1860, 1291
`(2016). [6]
`17. Lee, C.C., Julian, M.C., Tiller, K.E., Meng, F., DuConge, S.E.,† Akter, R., Raleigh, D.P., Tessier,
`P.M.,* “Design and optimization of anti-amyloid domain antibodies specific for Ab and IAPP”, J
`Biol Chem, 291, 2858 (2016). [19]
`18. Tiller, K.E., Tessier, P.M.,* “Advances in antibody design”, Ann Rev Biomed Eng, 17, 191 (2015).
`[52]
`19. Julian, M.C., Lee, C.L, Tiller, K.E., Rabia, L.A., Day, E.K.,† Schick III, A.J.,† Tessier, P.M.,* “Co-
`evolution of affinity and stability of grafted amyloid-motif domain antibodies”, Protein Eng Des
`Sel, 28, 339 (2015). [15]
`20. Wu, J, Schultz, J.S., Weldon, C.L., Sule, S.V., Chai, Q., Dickinson, C.D.,* Tessier, P.M.,*
`“Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction
`nanoparticle spectroscopy”, Protein Eng Des Sel, 28, 403 (2015). [14]
`21. McBride, S.A., Tilger, C.F., Sanford, S.P., Tessier, P.M., Hirsa, A.H.,* “Comparison of human and
`bovine insulin amyloidogenesis under uniform shear”, J Phys Chem B, 119, 10426 (2015). [12]
`22. Estep, P., Caffry, I., Yu, Y., Sun, T., Cao, Y., Leanaugh, H., Jain, T., Vásquez, M., Tessier, P.M.,
`Xu, Y.,* “An alternative assay to hydrophobic interaction chromatography for high-throughput
`characterization of monoclonal antibodies”, mAbs, 4, 553 (2015). [7]
`23. Li, X., Geng, S.B., Chiu, M.L., Saro, D., Tessier, P.M.,* “High-throughput assay for measuring
`monoclonal antibody self-association and aggregation in serum”, Bioconjug Chem, 26, 520 (2015).
`[7]
`24. Geng, S.B., Cheung, J.K., Narasimhan, C., Shameem, M., Tessier, P.M.,* “Improving monoclonal
`antibody selection and engineering using measurements of colloidal protein interactions”, J Pharm
`Sci, 103, 3356 (2014). [33]
`
`3 of 8
`
`Fresenius Kabi
`Exhibit 1002A
`
`

`

`25. Jayaraman, J., Wu, J., Brunelle,† M.C., Cruz, A.M., Goldberg, D.S., Lobo, B., Shah, A., Tessier,
`P.M.,* “Plasmonic measurements of monoclonal antibody self-association using self-interaction
`nanoparticle spectroscopy”, Biotech Bioeng, 11, 1513 (2014). [21]
`26. Tessier, P.M.,* Wu, J., Dickinson, C.G., “Emerging methods for identifying monoclonal antibodies
`with low propensity to self-associate during the early discovery process”, Expert Opin Drug Deliv,
`11, 461 (2014). [16]
`27. Perchiacca, J.M., Lee, C.C, Tessier, P.M.,* “Optimal charged mutations in the complementarity-
`determining regions that prevent domain antibody aggregation are dependent on the antibody
`scaffold”, Protein Eng Des Sel, 27, 29 (2014). [42]
`28. Liu, Y., Caffry, I., Wu, J., Geng, S.B., Jain, T., Sun, T., Reid, F., Cao, Y., Estep, P., Yu, Y.,
`Vásquez, M., Tessier, P.M., Xu, Y.,* “High-throughput screening for developability during early-
`stage antibody discovery using self-interaction nanoparticle spectroscopy”, mAbs, 6, 483 (2014).
`[36]
`29. Li, X., Zhang, X., Ladiwala, A.R.A, Du, D., Yadav, J.K., Tessier, P.M., Wright, P.E., Kelly, J.W.,
`Buxbaum, J.N.,* “Mechanisms of transthyretin inhibition of Ab aggregation in vitro”, J Neurosci,
`33, 19423 (2013). [55]
`30. Andersson, E.K., Bengtsson, C., Evans, M.L., Chorell, E., Sellstedt, M., Lindgren, A.E.G.,
`Hufnagel, D.A., Bhattacharya, M., Tessier, P.M., Wittung-Stafshede, P., Almqvist, F.,* Chapman,
`M.R.,* “Modulation of curli assembly and pellicle biofilm formation by chemical and protein
`chaperones”, Chem Biol, 20, 1245 (2013). [39]
`31. Lee, C., Perchiacca, J.M., Tessier, P.M.,* “Toward aggregation-resistant antibodies by design”,
`Trends Biotechnol, 31, 612 (2013). [57]
`32. Tiller, K.E., Tessier, P.M.,* “Lifting the veil on amyloid drug design”, eLife, 2, e00857 (2013). [4]
`33. Sule, S.V., Dickinson, C.G., Lu, J., Chow, C.-K., Tessier, P.M.,* “Rapid analysis of antibody self-
`association in complex mixtures using immunogold conjugates”, Mol Pharm, 10, 1322 (2013). [31]
`34. Ladiwala, A.R.A., Bhattacharya, M., Perchiacca, J.M., Cao, P., Raleigh, D.P., Abedini, A., Schmidt,
`A.M., Varkey, J., Langen, R., Tessier, P.M.,* “Rational design of potent domain antibody inhibitors
`of amyloid fibril assembly”, P Natl Acad Sci U S A, 109, 19965 (2012). [66]
`35. Perchiacca, J.M., Ladiwala, A.R.A., Bhattacharya, M., Tessier, P.M.,* “Aggregation-resistant
`domain antibodies engineered with charged mutations near the edges of the complementarity-
`determining regions”, Protein Eng Des Sel, 12, 591 (2012). [85]
`36. Ladiwala, A.R, Litt, J., Kane, R.S., Aucoin, D.S., Smith, S.O., Ranjan, S, Davis, J., Van Nostrand,
`W.E., Tessier, P.M.,* “Conformational differences between two amyloid b oligomers of similar size
`and dissimilar toxicity”, J Biol Chem, 287, 24765 (2012). [135]
`37. Ladiwala, A.R, Perchiacca, J.M., Fishman, Z.S.,† Bhattacharya, M., Domigan, B.,† Dordick, J.S.,
`Tessier, P.M.,* “Polyphenolic disaccharides endow proteins with unusual resistance to
`aggregation”, Biotech Bioeng, 109, 1869 (2012). [9]
`38. Perchiacca, J.M., Tessier, P.M.,* “Engineering aggregation-resistant antibodies”, Ann Rev Chem
`Biomol Eng, 3, 263 (2012). [79]
`39. Sule, S.V., Cheung, J., Antochshuk, V., Bhalla, A., Narasimhan, C., Blaisdell, S., Shameem, M.,
`Tessier, P.M.,* "Solution pH that minimizes self-association of three monoclonal antibodies is
`strongly dependent on ionic strength", Mol Pharm, 9, 744 (2012). [42]
`40. Perchiacca, J.M., Ladiwala, A.R.A, Bhattacharya, M.B., Tessier, P.M.,* "Structure-based design of
`conformation- and sequence-specific antibodies against amyloid b", P Natl Acad Sci U S A, 109, 84
`(2012). [89]
`41. Posada, D., Tessier, P.M., Hirsa, A.H.,* “Removal versus fragmentation of amyloid-forming
`precursors via membrane filtration”, Biotech Bioeng, 109, 840 (2012). [6]
`42. Sule, S.V., Sukumar, M., Weiss, W.F., Marcelino-Cruz, A.M., Sample, T.,† Tessier, P.M.,* "High-
`throughput analysis of concentration-dependent antibody self-association", Biophys J, 101, 1749
`(2011). [35]
`
`4 of 8
`
`Fresenius Kabi
`Exhibit 1002A
`
`

`

`43. Marcelino-Cruz, A.M., Bhattacharya, M., Anselmo, A.,† Tessier, P.M.,* “Site-specific structural
`analysis of a yeast prion strain with species-specific seeding activity”, Prion, 3, 208 (2011). [6]
`44. Ladiwala, A.R, Mora-Pale, M., Lin, J.C., Bale, S.S., Fishman, Z.S.,† Dordick, J.S., Tessier, P.M.,*
`“Polyphenolic glycosides and aglycones utilize opposing pathways to selectively remodel and
`inactivate toxic oligomers of amyloid β”, ChemBioChem, 12, 1749 (2011). [44]
`45. Perchiacca, J.M., Bhattacharya, M., Tessier, P.M.,* “Mutational analysis of domain antibodies
`reveals aggregation hotspots within and near the complementarity determining regions”, Proteins,
`79, 2637 (2011). [75]
`46. Ladiwala, A.R, Dordick, J.S., Tessier, P.M.,* “Aromatic small molecules remodel toxic soluble
`oligomers of amyloid Ab through three unique pathways”, J Biol Chem, 286, 3209 (2011). [150]
`47. Ladiwala, A.R, Lin, J.C., Bale, S.S., Marcelino-Cruz, A.M., Bhattacharya, M., Dordick, J.S.,
`Tessier, P.M.,* “Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Ab into
`off-pathway conformers”, J Biol Chem, 285, 24228 (2010). [240]
`48. Tessier, P.M.,* Lindquist, S.,* “Unraveling infectious structures, strain variants and species barriers
`for the yeast prion [PSI+]”, Nature Struct Mol Biol, 16, 598 (2009). [79]
`49. Bengali, A.N., Tessier, P.M.,* “Biospecific immobilization of proteins for rapid analysis of weak
`protein interactions using self-interaction nanoparticle spectroscopy”, Biotechnol Bioeng, 104, 240
`(2009). [11]
`50. Tessier, P.M.,* Jinkoji, J., Cheng, Y.C., Prentice, J.L., Lenhoff, A.M., “Self-interaction nanoparticle
`spectroscopy: A nanoparticle-based protein interaction assay”, J Am Chem Soc, 130, 3106 (2008).
`[56]
`51. Tessier P.M., Lindquist S.,* “Prion recognition elements govern nucleation, strain specificity and
`species barriers”, Nature, 447, 557 (2007).† [131]
`†See accompanying commentaries in Nature, 447, 541(2007), Nat Methods, 4, 538 (2007) & J
`Cell Biol, 177, 747 (2007).
`52. Tessier, P.M., Sandler, S.I., Lenhoff, A.M.,* “Direct measurement of protein osmotic second virial
`cross coefficients by cross-interaction chromatography”, Protein Sci, 13, 1379 (2004). [58]
`53. Tessier, P.M., Johnson, H.R., Pazhianur, R., Berger, B.W., Prentice, J.L., Bahnson, B.J., Sandler,
`S.I., Lenhoff, A.M.,* “Predictive crystallization of ribonuclease A via rapid screening of osmotic
`second virial coefficients,” Proteins, 50, 303 (2003). [81]
`54. Tessier, P.M., Lenhoff, A.M.,* “Measurement of protein self-association as a guide to
`crystallization,” Curr Opin Biotechnol, 14, 512 (2003). [81]
`55. Tessier, P.M., Verruto, V.J., Sandler, S.I., Lenhoff, A.M.,* “Correlation of diafiltration sieving
`behavior of lysozyme-BSA mixtures with osmotic second virial cross coefficients”, Biotechnol
`Bioeng, 87, 303 (2003). [24]
`56. Tessier, P.M., Lenhoff, A.M.,* Sandler, S.I., “Rapid measurement of protein osmotic second virial
`coefficients by self-interaction chromatography,” Biophys J, 82, 1620 (2002). [203]
`57. Tessier, P.M., Vandrey, S.D., Berger, B.W., Sandler, S.I., Lenhoff, A.M.,* “Self-interaction
`chromatography: A novel screening method for rational protein crystallization,” Acta Cryst D, 58,
`1531 (2002). [89]
`58. Tessier P.M., Christesen S.D., Ong K.K., Clemente E.M., Lenhoff A.M., Kaler E.W., Velev O.D.,*
`“On-line spectroscopic characterization of sodium cyanide with nanostructured gold SERS
`substrates,” Appl Spectrosc, 56, 1524 (2002). [56]
`59. Tessier P.M., Velev O.D.,* Kalambur A.T., Lenhoff A.M., Rabolt J.F., Kaler E.W., “Structured
`metallic films for optical and spectroscopic applications via colloidal crystal templating,” Adv
`Mater, 13, 396 (2001). [257]
`60. Tessier P.M., Velev O.D.,* Kalambur A.T., Rabolt J.F., Lenhoff A.M., Kaler E.W., “Assembly of
`gold nanostructured films templated by colloidal crystals and use in surface-enhanced Raman
`spectroscopy,” J Am Chem Soc, 122, 9554 (2000). [408]
`
`5 of 8
`
`Fresenius Kabi
`Exhibit 1002A
`
`

`

`
`
`2018
`
`2016
`
`
`
`2017
`
`61. Velev O.D.,* Tessier P.M., Lenhoff A.M., Kaler E.W., “A class of porous metallic nanostructures,”
`Nature, 401, 548 (1999). [612]
`INVITED SEMINARS (97 since 2007)
`2019
`McGill University, Depart. of Pharmacology & Therapeutics, Montreal, Canada (Oct 25)
`New York University, Dept. of Chemical & Biomolecular Engineering (Apr 26)
`Pfizer, Andover, MA (Apr 18)
`Pfizer, Cambridge, MA (Feb 28)
`Boehringer Ingelheim, Ridgefield, CT (Dec 7)
`University of Colorado, Boulder (Oct 18)
`Iowa State University, Department of Chemical & Biological Engineering (Sept 6)
`Roche Diagnostics, Penzberg, Germany (Aug 22)
`University of Natural Resources and Life Sciences, Vienna, Austria (Aug 20)
`Bayer HealthCare, Wuppertal, Germany (Aug 15)
`Adimab, Lebanon, NH (Jul 16)
`University of Washington, Dept. of Bioengineering (Apr 19)
`Texas A&M, Department of Biochemistry & Biophysics (Feb 28)
`University of California, Santa Barbara, Dept. of Chemical Engineering (Apr 20)
`Sanofi, Framingham, MA (Apr 11)
`Univ. of Michigan, Dept. of Chemical Engineering (Jan 31)
`Univ. of Michigan, Dept. of Department of Pharmaceutical Sciences (Nov 2)
`Univ. of North Carolina, Charlotte, Dept. of Chemistry (Oct 27)
`Imperial College, Department of Chemical Engineering, London, England (Oct 21)
`Bayer HealthCare, Wuppertal, Germany (Jul 11)
`University of Zurich, Dept. of Biochemistry, Switzerland (Jul 6)
`University of Pennsylvania, Dept. of Chemical & Biomolecular Engineering (Apr 20)
`Genor BioPharma, Shanghai, China (Apr 13)
`Pfizer, Cambridge, MA (Feb 25)
`Regeneron Pharmaceuticals, Tarrytown, NY (Jan 29)
`Brooklyn College, Dept. of Biology (Dec 10)
`DuPont, Palo Alto, CA (Dec 2)
`University of Maryland, Dept. of Bioengineering (Nov 20)
`Boehringer Ingelheim, Ridgeway, CT (Oct 9)
`Amgen, Thousand Oaks, CA (Aug 27)
`Morphosys, Martinsried, Germany (Jul 16)
`Technische Universität München, Freising-Weihenstephan, Germany (Jul 14)
`Technische Universität München, Garching, Germany (Jul 1)
`Novo Nordisk, Måløv, Denmark (Jun 15)
`Ludwig-Maximilians-Universität München, Dept. of Pharmacy, Germany (May 21)
`KULeuven, Department of Cellular and Molecular Medicine, Leuven, Belgium (Apr 29)
`Schrödinger, New York, NY (Jan 15)
`Bristol-Myers Squibb, New Brunswick, NJ (Jan 9)
`Boehringer Ingelheim, Biberach, Germany (Nov 13)
`Max Planck Institute of Biochemistry, Martinsried, Germany (Sept 24)
`University of California, Riverside, Dept of Chemical & Environmental Eng. (Jun 6)
`Johns Hopkins University, Dept. of Chemical & Biomolecular Eng. (Apr 24)
`Roche Diagnostics, Penzberg, Germany (Apr 2)
`Bayer HealthCare, Wuppertal, Germany (Mar 28)
`University of Michigan, Dept of Molecular, Cellular, & Developmental Biology (Mar 21)
`
`
`
`
`
`
`
`
`
`2015
`
`2014
`
`6 of 8
`
`Fresenius Kabi
`Exhibit 1002A
`
`

`

`2013
`
`
`
`
`
`2012
`
`
`
`2011
`
`
`
`
`2010
`
`
`
`2009
`
`2008
`
`2007
`
`University of Illinois, Urbana-Champaign, Dept. of Chem. & Biomol. Engineering (Dec 12)
`MIT, Dept. of Chemical Engineering (Nov 22)
`Merrimack Pharmaceuticals, Cambridge, MA (Nov 21)
`Rutgers University, Dept. of Chemical & Biological Engineering (Oct 3)
`Chinese Academy of Sciences, Institute for Biophysics, Beijing, China (Jun 14)
`Chinese Academy of Sciences, Institute for Process Engineering, Beijing, China (Jun 13)
`Merck Research Labs, Summit, NJ (May 21)
`University of California, Santa Barbara, Dept. of Chemical Engineering (May 16)
`Ohio State University, Dept. of Chemical & Biomolecular Engineering (Apr 18)
`Adimab, Lebanon, NH (Apr 2)
`University of Texas, Austin, Dept. of Chemistry and Biochemistry (Feb 22)
`University of California, Berkeley, Dept. of Chemical & Biomolecular Eng. (Feb 20)
`Pfizer, Andover, MA (Dec 10)
`Lehigh University, Dept. of Chemical Engineering (Dec 5)
`University of Colorado, Boulder, Dept. of Chemical & Biological Engineering (Nov 27)
`DuPont Experimental Station, Wilmington, DE (Nov 16)
`University of Wisconsin, Madison, Dept. of Chemical & Biological Engineering (Oct 9)
`Bristol-Myers Squibb, New Brunswick, NJ (Jul 24)
`University of New Hampshire, NSF Biomolecular Interactive Technologies Center (Jul 16)
`University of Delaware, Dept. of Chemical Engineering (May 4)
`Tulane University, Dept. of Chemical & Biomolecular Engineering (Apr 20)
`University of Florida, College of Medicine (Mar 7)
`University of Pennsylvania, Dept. of Biochemistry & Biophysics (Jan 19)
`Janssen Pharmaceuticals (Johnson & Johnson), Radnor, PA (Jan 18)
`Tufts University, Dept. of Chemical & Biological Engineering (Nov 14)
`Abbott Laboratories, Worchester, MA (Nov 4)
`Stony Brook University, Center for Structural Biology (Apr 8)
`Applied Molecular Evolution, San Diego (Mar 25)
`University of Maine, Dept. of Chemical & Biological Engineering (Feb 25)
`Eli Lilly, Indianapolis, IN (Feb 11)
`Merck, Union, NJ (Feb 3)
`Syracuse University, Dept. of Biomedical & Chemical Engineering (Nov 18)
`Bristol-Myers Squibb, New Brunswick, NJ (Jun 30)
`Genentech, South San Francisco, CA (Mar 24)
`University of Kansas, Dept. of Pharmaceutical Chemistry (Feb 16)
`MedImmune, Gaithersburg, MD (Dec 15)
`University of Cincinnati, Dept. of Chemistry (Oct 30)
`National Institute of Standards and Technology, Gaithersburg, MD (Oct 14)
`Biogen, Cambridge, MA (Apr 1)
`Amgen, Seattle, WA (Oct 2)
`Schering-Plough, Schering-Plough Research Institute, Union, NJ (Aug 14)
`Georgia Institute of Technology, Dept. of Biology (Apr 18)
`Rensselaer Polytechnic Institute, Dept. of Biology (Feb 15)
`Yale University, Dept. of Chemical Engineering (Apr 24)
`Johns Hopkins University, Dept. of Chemical and Biomolecular Engineering (Apr 5)
`University of Massachusetts (Amherst), Dept. of Chemical Engineering (Mar 27)
`Northwestern University, Dept. of Chemical & Biological Engineering (Mar 15)
`
`
`
`
`
`7 of 8
`
`Fresenius Kabi
`Exhibit 1002A
`
`

`

`Cornell University, School of Chemical & Biomolecular Engineering (Mar 8)
`North Carolina State University, Dept. of Chemical & Biomolecular Engineering (Feb 28)
`University of Virginia, Dept. of Chemical Engineering (Feb 22)
`
`
`GRANTS (36 grants totaling >$6M since 2008)
`
`AWARDS RECEIVED BY LAB MEMBERS
`Postdoctoral associates
`• NIH F32 Postdoctoral Fellowship, Charles Starr, 2018
`Graduate students
`• NSF Graduate Fellowship, Kathryn Tiller, 2011
`• NSF Graduate Fellowship, Mark Julian, 2012
`• NSF Graduate Fellowship, Lilia Rabia, 2013
`• W.H. Peterson Award for Best Student Oral Presentation, Division of Biochemical Technology,
`American Chemical Society National Meeting, Joseph Perchiacca, 2013
`• W.H. Peterson Award for Best Student Poster Presentation, Division of Biochemical
`Technology, American Chemical Society National Meeting, Shantanu Sule, 2013
`Undergraduate students
`• NSF Graduate Fellowship, Evan Day (to attend UPenn, now at University of Virginia), 2014
`• NSF Graduate Fellowship, Malaney Young (to attend the University of Minnesota), 2017
`• NSF Graduate Fellowship, Daniel Wackelin (to attend CalTech), 2018
`
`
`SYNERGISTIC ACTIVITIES
`Co-chair, Division of Biochemical Technology Meeting (San Diego), American Chemical Society (Mar
`2016)
`Co-chair, 7th International Conference on Biomolecular Engineering, Society of Biological Engineering
`(Jan 2017)
`Vice-chair, 2nd Gordon Research Conference on Biotherapeutics and Vaccines Development (expected
`2021)
`Co-chair, 3rd Gordon Research Conference on Biotherapeutics and Vaccines Development (expected
`2023)
`Session chair, Frontiers in Engineering, US National Academy of Engineering, Irvine, CA, 2016
`Membership Chair, Division of Biochemical Technology, American Chemical Society, 2009-2013
`Editorial Board Member, Journal of Biological Chemistry, 2013-2018
`Review Editor, Frontiers in Molecular Biosciences, 2014-present
`National Science Foundation Panelist, 2008-2013 (6)
`National Institutes of Health Panelist, 2015-2017 (3)
`New Visions Math, Engineering, Science and Technology Instructor (for high school seniors), 2009-
`2013
`
`8 of 8
`
`Fresenius Kabi
`Exhibit 1002A
`
`